Abstract

Patients with augmented renal clearance (ARC) have been described as having low vancomycin concentration. However, the pharmacokinetic model that best describes vancomycin in patients with ARC has not been clarified. The purpose of this study is to determine the pharmacokinetic of vancomycin in Chinese adults and the recommend dosage for patients with different renal function, including patients with ARC. We retrospectively collected 424 vancomycin serum concentrations from 209 Chinese patients and performed a population pharmacokinetic model using NONMEM 7.4.4. The final model indicated that the clearance rate of vancomycin increased together with the creatinine clearance, and exhibited a nearly saturated curve at higher creatinine clearance. The estimated clearance of vancomycin was between 3.46 and 5.58 L/h in patients with ARC, with 5.58 being the maximum theoretical value. The central volume of distribution increased by more than three times in patients admitted to Intensive Care Unit. Monte Carlo simulations were conducted to explore the probability of reaching the target therapeutic range (24-h area under the curve: 400–650 mg·h/L, trough concentration: 10–20 mg/L) when various dose regimens were administered. The simulations indicated that dose should increase together with the creatinine clearance until 180 mL/min. These findings may contribute to improving the efficacy and safety of vancomycin in patients with ARC.

Highlights

  • Vancomycin is a glycopeptide antibiotic used to treat a number of gram-positive infections [1]

  • It is the first-line choice of treatment for infections caused by methicillinresistant Staphylococcus aureus (MRSA)

  • Vancomycin was administered at different dosages, and mostly evaluated between 5 and 12 h after administration

Read more

Summary

Introduction

Vancomycin is a glycopeptide antibiotic used to treat a number of gram-positive infections [1]. It is the first-line choice of treatment for infections caused by methicillinresistant Staphylococcus aureus (MRSA). The clearance rate is mainly affected by renal function. Dosage must be adjusted for patients with renal dysfunction because the risk of toxicity is increased by high blood concentrations [3]. Patients with augmented renal clearance (ARC) have lower concentrations of vancomycin, leading to suboptimal drug exposure and treatment failure [4,5]. The administration of subtherapeutic doses increased the prevalence of antibiotic resistance [8]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call